Thermo Fisher Scientific (NYSE:TMO) Shares Gap Down to $547.25

Thermo Fisher Scientific Inc. (NYSE:TMO) gapped down before the market opened on Thursday . The stock had previously closed at $547.25, but opened at $534.80. Thermo Fisher Scientific shares last traded at $537.63, with a volume of 340,357 shares changing hands.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TMO. Evercore ISI upped their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Raymond James raised their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. TheStreet raised shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research note on Friday, December 22nd. Royal Bank of Canada boosted their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Finally, Barclays cut Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $475.00 to $555.00 in a research note on Wednesday, January 24th. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $604.69.

Thermo Fisher Scientific Trading Down 0.8 %

The business has a 50 day moving average price of $571.57 and a 200 day moving average price of $527.01. The company has a market capitalization of $207.31 billion, a P/E ratio of 35.42, a PEG ratio of 2.33 and a beta of 0.80. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. During the same quarter last year, the firm posted $5.40 earnings per share. Thermo Fisher Scientific’s revenue was down 4.9% compared to the same quarter last year. Analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a dividend of $0.39 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.10%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now owns 1,207 shares in the company, valued at $660,192.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 5,547 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $550.62, for a total value of $3,054,289.14. Following the completion of the transaction, the chief executive officer now owns 43,608 shares of the company’s stock, valued at $24,011,436.96. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of TMO. Northwest Financial Advisors acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. True Wealth Design LLC boosted its position in Thermo Fisher Scientific by 1,275.0% during the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock worth $29,000 after purchasing an additional 51 shares during the period. Coppell Advisory Solutions LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter valued at about $33,000. Live Oak Investment Partners acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $36,000. Finally, Tyler Stone Wealth Management acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $37,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.